Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

1d ago, source:

Analysts have set 12-month price targets for Kymera Therapeutics, revealing an average target of $53.0, a high estimate of ...

Kymera Therapeutics gets grant for treatment of crbn-mediated disorders using specific compounds

7h ago, source: Pharmaceutical Technology

Discover how Kymera Therapeutics Inc's patent revolutionizes treatment for CRBN-mediated disorders, including leukemia, lymphomas, Alzheimer's, and more.

Kymera Therapeutics (NASDAQ: KYMR)

4d ago, source: The Motley Fool

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was ...

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

15d ago, source: Yahoo Finance

WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using ...

Kymera Therapeutics Inc Ordinary Shares KYMR

11d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Kymera Therapeutics, Inc. Common Stock (KYMR)

2mon ago, source: Nasdaq

NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...

Kymera Therapeutics Inc Ordinary Shares

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Kymera Therapeutics Inc.

2mon ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

15d ago, source: Finanznachrichten

April 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein ...

Kymera Therapeutics Inc (KYMR)

28d ago, source: Investing

Investing.com - Kymera (NASDAQ: KYMR) reported first quarter EPS of $-0.70, $0.01 worse than the analyst estimate of $-0.69. Revenue for the quarter came in at $9.5M versus the ...